Biosig Technologies, INC DEF 14A proxy statements

Streamex Corp. is calling its 2025 Annual Meeting to elect directors, approve executive compensation, and significantly increase its long-term incentive plan shares by over 22 million.

Streamex Corp. announced Nasdaq approval for continued listing and will reconvene a special shareholder meeting on November 4, 2025, to vote on an acquisition proposal.

BioSig Technologies' stockholders approved significant increases in authorized shares, a long-term incentive plan amendment, and a classified board, while adjourning a vote on shares for the Streamex acquisition.

BioSig Technologies announced the adjournment of a key shareholder vote for its Streamex merger due to pending Nasdaq approval, though the merger itself and company operations remain unaffected.

BioSig Technologies, Inc. announced an amendment to its proxy statement, adjourning the vote on the Streamex acquisition proposal to a later date pending Nasdaq approval.

BioSig Technologies, Inc. has withdrawn the proposal for stockholder approval of share issuance related to its Streamex acquisition from the upcoming Special Meeting.

BioSig Technologies, Inc. filed an amendment to its definitive proxy statement, revising details of its convertible debenture financing with Yorkville and clarifying the absence of a financial advisor for the Streamex acquisition.

BioSig Technologies, Inc. seeks shareholder approval for a strategic pivot into tokenized finance via the acquisition of Streamex Exchange Corporation, alongside significant capital raises and governance changes, leading to substantial dilution for existing shareholders.

BioSig Technologies has filed its definitive proxy statement with the Securities and Exchange Commission.

BioSig Technologies is asking shareholders to vote on a reverse stock split and an amendment to their long-term incentive plan at the upcoming annual meeting.